Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?

Abstract

The somatostatin (SS) receptor scintigraphy (SRS), using octreotide radiolabelled with 111In (Ocreoscan©, OCT), is a consolidated diagnostic procedure in patients with neuroendocrine tumors (NET) because of an increased expression of somatostatin receptors (SS-R) on neoplastic cells. Uptake of SS analogues (SSA) can also be due to SS-R expression on nonmalignant cells when activated as lymphocytes, macrophages, fibroblasts, vascular cells. Because of this uptake, clinical indications can be found either in neoplasms not overexpressing SS-R, as nonsmall cell lung cancer, and in active benign diseases. Nevertheless, clinical application of SRS has not found clinical relevance yet. In this paper, we discuss the nononcologic fields of clinical interest in which SRS could play a clinical role such as diagnosis, prognosis, and therapy of benign and chronic diseases such as sarcoidosis, histiocytosis, rheumatoid arthritis, idiopathic pulmonary fibrosis, and Graves' ophthalmopathy.

Keywords

Autoimmune diseases - diagnostic imaging - Graves’ ophthalmopathy - octreotide - osteomalacia - paraneoplastic syndromes - sarcoidosis - somatostatin

Publication History

Article published online:
27 July 2021

• References

• 1 Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
• 2 Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
• 3 Patel YE. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98.
• 4 Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: Facts and artifacts. J Clin Endocrinol Metab 1999;84:2942-50.
• 5 Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003;20:255-64.
• 6 Cuccurullo V, Cascini GL, Tamburrini O, Mansi L, Rotondo A. Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest. Minerva Endocrinol 2011;36:41-52.
• 7 Van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine 2003;20:307-11.
• 8 Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Peptide imaging with somatostatin analogues: More than cancer probes. Curr Radiopharm 2013;6:36-40.
• 9 Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue (s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10(Suppl 2):S23-9.
• 10 Cuccurullo V, Faggiano A, Scialpi M, Cascini GL, Piunno A, Catalano O, et al. Questions and answers: What can be said by diagnostic imaging in neuroendocrine tumors? Minerva Endocrinol 2012;37:367-77.
• 11 Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
• 12 Mansi L, Cuccurullo V. Diagnosticimaging in neuroendocrine tumors. J Nucl Med 2014;55:1576-7
• 13 Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
• 14 Cuccurullo V, Mansi L. Toward tailored medicine (and beyond): The phaeochromocytoma and paraganglioma model. Eur J Nucl Med Mol Imaging 2012;39:1262-5.
• 15 Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93.
• 16 Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111) Inpentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49:225-35.
• 17 Cascini GL, Cuccurullo V, Mansi L. The non tumour uptake of (111) In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging 2010;54:24-36.
• 18 Velikyan I. 68Ga-Based radiopharmaceuticals: Production and application relationship. Molecules 2015;20:12913-43.
• 19 Ambrosini V, Nanni C, Fanti S. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. PET Clin 2014;9:323-9.
• 20 Ambrosini V, Morigi JJ, Nanni C, Castellucci P, Fanti S. Current status of PET imaging of neuroendocrine tumours ([18F] FDOPA, [68Ga] tracers, [11C]/[18F]-HTP). Q J Nucl Med Mol Imaging 2015;59:58-69.
• 21 Rambaldi PF, Cuccurullo V, Cascini GL, Mansi L. Our experience in thymic hyperplasia using 67Ga-citrate, 111In-pentetreotide and 201Tl-chloride. Eur J Nucl Med Mol Imaging 2010;37:1616.
• 22 Briganti V, Matteini M, Ferri P, Vaggelli L, Castagnoli A, Pieroni C. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm 2001;16:515-24.
• 23 Cascini GL, Cuccurullo V, Tamburrini O, Mansi L, Rotondo A. Nuclear medicine in multiple myeloma - more thandiagnosis. Nucl Med Rev Cent East Eur 2010;13:32-8.
• 24 Kamphuis LS, Kwekkeboom DJ, Missotten TO, Baarsma GS, Dalm VA, Dik WA, et al. Somatostatin receptor scintigraphy patterns in patients with sarcoidosis. Clin Nucl Med 2015;40:925-9.
• 25 Lebtahi R, Crestani B, Belmatoug N, Daou D, Genin R, Dombret MC, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001;42:21-6.
• 26 Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998;25:1284-92.
• 27 Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47:1281-7.
• 28 Cuccurullo V, Cascini G, Rossi A, Tamburrini O, Rotondo A, Mansi L. Pathophysiological premises to radiotracers for bone metastases. Q J Nucl Med Mol Imaging 2011;55:353-73.
• 29 Cuccurullo V, Cascini GL, Tamburrini O, Rotondo A, Mansi L. Bone metastasesradiopharmaceuticals: An overview. Curr Radiopharm 2013;6:41-7.
• 30 Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
• 31 Smith TJ. Pathogenesis of Graves' orbitopathy: A 2010 update. J Endocrinol Invest 2010;33:414-21.
• 32 Förster GJ, Krummenauer F, Nickel O, Kahaly GJ. Somatostatin-receptor scintigraphy in Graves' disease: Reproducibility and variance of orbital activity. Cancer Biother Radiopharm 2000;15:517-25.
• 33 Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med 1995;36:550-4.
• 34 Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oei HY, van den Bosch WA, et al. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity? J Clin Endocrinol Metab 1994;79:1845-51.
• 35 Mansi L, Rambaldi PF, Bizzarro A, Panza N, Di Martino S, De Bellis A, et al. E. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos. Q J Nucl Med 1995;39:105-10.
• 36 Santini M, Rambaldi PF, Di Lieto E, Cuccurullo V, Vicidomini G, Di Crescenzo VG, et al. Role of radio-guided surgery with 111In-octreotide in the treatment of thoracic neoplasms. Minerva Endocrinol 2001;26:285-8.
• 37 Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 1995;42:571-80.
• 38 Mansi L, Cuccurullo V. Diagnostic imaging in neuroendocrine tumors. J Nucl Med 2014;55:1576-7.
• 39 Dadoniene J, Miglinas M, Miltiniene D, Vajauskas D, Seinin D, Butenas P, et al. Tumour-induced osteomalacia: A literature review and a case report. World J Surg Oncol 2016;14:4.
• 40 Teves DA. Clinical Approach of Cushing Syndrome Resulting From ACTH-Producing Metastatic Neuroendocrine Tumor. Endocrinologist 2005;15:401-4.
• 41 Witek P, Witek J, Zieliński G, Podgajny Z, Kamiński G. Ectopic Cushing's syndrome in light of modern diagnostic techniques and treatment options. Neuroendocrinol Lett 2015;36:201-8.
• 42 Doppman JL, Travis WD, Nieman L, Miller DL, Chrousos GP, Gomez MT, et al. Cushing syndrome due to primary pigmented nodular adrenocortical disease: Findings at CT and MR imaging. Radiology 1989;172:415-20.
• 43 Pelosof LC, Gerber DE. Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc 2010;85:838-54.
• 44 Kulkarni HR, Singh A, Baum RP. Advances in the Diagnosis of Neuroendocrine Neoplasms. Semin Nucl Med 2016;46:395-404.
• 45 Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 2010;95:1207-19.
• 46 Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging 2012;39:1519-24.
• 47 Drezner MK. Tumorinducedosteo-malacia. In: Favus MJ, editor. Primer on metabolic bone disease and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott-Raven; 1999. pp 319-37.
• 48 Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone 2014;64:222-7.
• 49 Seufert J, Ebert K, Müller J, Eulert J, Hendrich C, Werner E, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001;345:1883-8.
• 50 Paglia F, Dionisi S, Minisola S. Octreotide for tumor-induced osteomalacia. N Engl J Med 2002;346:1748-9.
• 51 Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH, et al. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol 2007;81:167-74.
• 52 Grzbiela H, Tarnawski R, D'Amico A, Stąpór-Fudzińska M. The Use of 68Ga-DOTA-(Tyr3)-Octreotate PET/CT for Improved Target Definition in Radiotherapy Treatment Planning of Meningiomas. Curr Radiopharm 2015;8:45-8.
• 53 Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46:763-9.
• 54 Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. Acta Oncol 2013;52:514-20.
• 55 Haugen IK, Hammer HB. A need for new imaging modality to detect inflammation in rheumatoid arthritis and osteoarthritis? Ann Rheum Dis 2016;75:479-80.
• 56 Vanhagen PM, Markusse HM, Lamberts SW, Kwekkeboom DJ, Reubi JC, Krenning EP. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 1994;37:1521-7.
• 57 Weinmann P, Crestani B, Tazi A, Genereau T, Mal H, Aubier M, et al. 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis. J Nucl Med 2000;41:1808-12.
• 58 Dalm VA, van Hagen PM, Krenning EP. The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis. Q J Nucl Med 2003;47:270-8.
• 59 Kierans A, Parikh N, Chandarana H. Recent Advances in MR Hardware and Software. Radiol Clin North Am 2015;53:599-610.
• 60 Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012;42:190-207.
• 61 Adams S, Baum RP, Hertel A, Wenisch HJ, Staib-Sebler E, Herrmann G, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155-
• 62 Kitson SL, Cuccurullo V, Moody TS, Mansi L. Radionuclide antibody-conjugates, a targeted therapy towards cancer. Curr Radiopharm 2013;6:57-71.